admin – Page 3491 – Get News Story

Top Real Estate Listing Agent in Wesley Chapel, FL, Empowers Clients with Full-Spectrum Home Selling and Buying Services

Wesley Chapel, FL – Whether buying or selling, having the right real estate professional makes all the difference. Michelle Moreno, a top real estate listing agent in Wesley Chapel, FL, is dedicated to providing a comprehensive, client-first approach that simplifies the process and ensures success. With her in-depth market expertise and strong negotiation skills, Michelle helps clients navigate today’s real estate landscape with confidence.

For sellers, Michelle offers tailored strategies to showcase properties effectively and attract serious buyers. She focuses on market-driven pricing, professional marketing, and personalized staging advice to maximize a home’s appeal. “Selling a home is more than just putting it on the market—it’s about creating a strategy that gets results,” says Michelle Moreno, Realtor in Wesley Chapel, FL. “I take a hands-on approach to help my clients prepare, price, and position their homes for the best possible outcome.”

On the buying side, Michelle ensures clients have the knowledge and tools to make informed decisions. As one of the most trusted Wesley Chapel, FL Realtors, she takes the time to understand her clients’ needs, providing expert insights on financing, market trends, and negotiation tactics. Her goal is to make the process as seamless as possible, whether helping first-time buyers or those upgrading to a new home.

Beyond her role as a real estate professional, Michelle values community connections and believes in giving back. Her commitment to service, integrity, and strong client relationships has set her apart among real estate selling agents in Wesley Chapel, FL. By prioritizing her clients’ best interests, she has built a reputation for delivering exceptional results and ensuring smooth, stress-free transactions.

For those looking to buy or sell in Wesley Chapel, Michelle Moreno offers a well-rounded approach backed by market knowledge and a deep commitment to client success. “I work tirelessly to make sure my clients have all the resources and support they need,” she says. Visit https://keytosold.kw.com to learn more about her services or to schedule a consultation.

Media Contact
Company Name: Key to Sold Team | Keller Williams Tampa Properties | Real Estate Agent in Wesley Chapel FL
Contact Person: Michelle Moreno
Email: Send Email
Phone: +1 813-523-6613
City: Wesley Chapel
State: Florida
Country: United States
Website: https://keytosold.kw.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Real Estate Listing Agent in Wesley Chapel, FL, Empowers Clients with Full-Spectrum Home Selling and Buying Services

The Hepatitis A Market is Expected to see Robust Growth by 2032, Driven by Novel Therapeutic Approaches and Rising Disease Prevalence | DelveInsight

“Hepatitis A Market DelveInsight research”

The Hepatitis A market is projected to experience robust growth, fueled by the launch of innovative therapies, rising disease prevalence, and heightened healthcare investments across key regions. Industry leaders, including Boryung Pharmaceutical, Cadila Healthcare, Indian Immunologicals, Biological E Limited, Sinovac Biotech Co., Ltd, Sanofi, GlaxoSmithKline, Crucell Holland BV, and Merck, among others, are at the forefront of research and development initiatives in this therapeutic area.

DelveInsight’s latest report titled “Hepatitis A Market Insights, Epidemiology, and Market Forecast – 2032,” covers in-depth market assessments across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, providing critical insights into Hepatitis A current treatment paradigms and future market dynamics.

According to the latest comprehensive analysis in the report, the market is set to expand significantly during the forecast period, primarily attributed to the rising vaccination rates, public health campaigns targeting sanitation improvements, and advancements in therapeutic development. Among 7MM, the United States remains the largest contributor to the Hepatitis A market, attributed to its advanced healthcare infrastructure, high vaccination coverage, and proactive government initiatives to curb outbreaks.

Download the Hepatitis A market report to understand which factors are driving the Hepatitis A therapeutic market @ Hepatitis A Market Trends.

A recent hepatitis A outbreak in the Netherlands has been linked to contaminated frozen blueberries, underscoring how poor hygiene and inadequate sanitation can also lead to an increase in Hepatitis A prevalence.

Hepatitis A, a highly contagious liver infection caused by the Hepatitis A virus (HAV), continues to pose substantial public health challenges globally. The DelveInsight report’s epidemiological analysis indicates a significant patient pool across the 7MM, with detailed segmentation providing valuable insights into disease patterns and prevalence trends. The diagnosed Hepatitis A cases are steadily increasing across the 7MM.

In the US and EU4 nations, outbreaks are linked to international travel and high-risk behaviors, underscoring the need for targeted vaccination programs. Japan’s aging population presents unique challenges as older adults face higher risks of severe complications, including cholestatic hepatitis and acute liver failure.

The report’s epidemiological forecasts offer stakeholders a comprehensive understanding of the current and future patient landscape, essential for strategic planning and resource allocation in clinical development.

Discover evolving trends in Hepatitis A patient pool forecasts @ Hepatitis A Epidemiology Analysis.

The report also analyses the current and emerging therapeutic landscape for Hepatitis A. Among the marketed therapies for Hepatitis A, three key vaccines dominate the landscape: HAVRIX, VAQTA, and TWINRIX.

HAVRIX, developed by GSK, is an inactivated vaccine that stimulates the immune system to produce antibodies against the Hepatitis A virus (HAV). Similarly, VAQTA (Merck) is another inactivated vaccine that provides enduring protection against HAV through antibody generation. TWINRIX, also from GSK, is a combination vaccine targeting both Hepatitis A and Hepatitis B and has gained traction among travelers and healthcare workers, aligning with the World Health Organization’s (WHO) recommendations for high-risk groups. AVAXIM, an inactivated vaccine, is also used for hepatitis A prevention for both adults and children over one year old

The Hepatitis A clinical pipeline is witnessing notable advancements, with several emerging therapies in late-stage clinical development aimed at enhancing prevention strategies and addressing unmet needs in high-risk populations. These emerging therapies focus on novel mechanisms of action, including monoclonal antibodies and next-generation antiviral agents, which promise to redefine treatment paradigms. DelveInsight’s analysis underscores the potential of these pipeline assets to capture significant market share post-launch, with key players leveraging strategic licensing agreements and partnerships to accelerate development timelines.

Recently, research published in January 2025 has shown promising advancements in Hepatitis A vaccine technology. Scientists have successfully developed a reverse genetically modified HAV vaccine strain (RG-HAV) with enhanced replication capacity when adapted to Vero cells. This development addresses a significant challenge in HAV vaccine production, which has historically been limited by slow replication rates and reliance on diploid cell lines like MRC-5.

Unlock which Hepatitis A emerging drug is expected to capture the largest market share in 7MM by 2032. Visit the Hepatitis A Drug Insights.

The comprehensive analysis of the Hepatitis A market indicates promising growth prospects through 2032, supported by advancements in disease understanding, expanding therapeutic options, and increasing healthcare priorities. Stakeholders across the pharmaceutical industry, healthcare providers, and investors can leverage these insights to navigate the evolving landscape effectively and contribute to improved patient outcomes in Hepatitis A management. As pipeline candidates progress toward commercialization and market dynamics continue to evolve, strategic positioning based on robust market intelligence will be instrumental in maximizing opportunities in this growing therapeutic area.

Table of Contents

1.	Key Insights
2.	Executive Summary of Hepatitis A
3.	Hepatitis A Competitive Intelligence Analysis
4.	Hepatitis A Market Overview
5.	Hepatitis A: Disease Background and Overview
6.	Hepatitis A Patient Journey
7.	Hepatitis A Epidemiology and Patient Population
8.	Treatment Algorithm, Current Treatment, and Medical Practices
9.	Hepatitis A Unmet Needs
10.	Key Endpoints of Hepatitis A Treatment
11.	Hepatitis A Marketed Products
12.	Hepatitis A Emerging Therapies
13.	Hepatitis A: Seven Major Market Analysis
14.	Attribute analysis
15.	7MM: Market Outlook
16.	Access and Reimbursement Overview of Hepatitis A
17.	KOL Views
18.	Hepatitis A Market Drivers
19.	Hepatitis A Market Barriers
20.	Appendix
21.	DelveInsight Capabilities
22.	Disclaimer
23.	About DelveInsight

Related Reports

Hepatitis A Pipeline Insight

Hepatitis A Pipeline Insight provides comprehensive insights about the Hepatitis A pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Hepatitis A companies, including Boryung Pharmaceutical, Cadila Healthcare, Indian Immunologicals, and Biological E Limited, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Hepatitis A Market is Expected to see Robust Growth by 2032, Driven by Novel Therapeutic Approaches and Rising Disease Prevalence | DelveInsight

The Ocular Melanoma Market is Expected to Grow Substantially from USD 340 Million in 7MM by 2034 | DelveInsight

“Ocular Melanoma Market Research DelveInsight”

The 7MM ocular melanoma market is expected to grow substantially in the next 10 years, fueled by advancements in diagnostics and therapeutics, an increasing disease prevalence, and rising healthcare investments globally. Leading Ocular Melanoma companies include Bristol Myers Squibb, Merck & Co., Inc., Novartis AG, Roche Holding AG, Pfizer Inc., AstraZeneca PLC, Eli Lilly and Company, Bayer AG, GlaxoSmithKline PLC, Amgen Inc., among others.

DelveInsight’s latest report, “Ocular Melanoma – Market Insight, Epidemiology And Market Forecast – 2034”, combines robust epidemiological data with ocular melanoma market trends, competitive landscape analysis, and patient journey assessments in the 7MM which includes the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The report predicts that the ocular melanoma market is expected to grow positively in 7MM from approximately USD 340 million in 2023 during the forecast period (2024–2034). The US leads the market among 7MM, with a 60% market share in 2023, followed by the United Kingdom. Among the EU4 countries and the UK, the UK has the largest market size for ocular melanoma, while Spain holds the smallest share.

Download the Ocular Melanoma Market report to understand which factors are driving the Ocular Melanoma therapeutic market @ Ocular Melanoma Market Trends.

The report also analyzes historical and projected ocular melanoma epidemiology, segmented by ocular melanoma diagnosed incident cases, region-specific ocular melanoma cases, type-specific ocular melanoma cases, mutation-specific ocular melanoma cases, age-specific ocular melanoma cases, stage-specific ocular melanoma cases, and total treated cases of ocular melanoma.

The ocular melanoma patient pool is significant in the 7MM, with the US accounting for the highest number of diagnosed incident cases. Ocular melanoma primarily affects individuals aged 40–70, with a higher incidence in fair-skinned individuals and those with lighter eye colors. Other risk factors include dysplastic nevus syndrome, certain cutaneous nevi, and a family history of systemic and ocular cancers.

Ocular melanoma can be divided into uveal and non-uveal melanoma. Uveal melanoma comprises the larger group of ocular melanoma, with approximately 95% of all ocular melanoma cases, and includes choroidal, ciliary body, and iris melanoma. Non-uveal melanoma consists of conjunctival melanoma and other ocular melanomas originating from different sites.

Discover evolving trends in the Ocular Melanoma patient pool forecasts @ Ocular Melanoma Epidemiology Analysis.

The ocular melanoma market report also offers insights into current ocular melanoma treatment practices, emerging drugs, market share of individual therapies, and forecasts for the 7MM ocular melanoma market size from 2020 to 2034. Several innovative therapies have been approved by the FDA for treating ocular melanoma. KIMMTRAK (Immunocore) is a groundbreaking immunotherapy and the first FDA-approved metastatic uveal melanoma drug. Another significant therapy is HEPZATO KIT (Delcath Systems), a targeted hepatic artery infusion chemotherapy that delivers high doses of melphalan directly to the liver, where metastatic uveal melanoma often spreads, thus minimizing systemic side effects.

Additionally, immune checkpoint inhibitors such as YERVOY (BMS), which targets CTLA-4, and OPDIVO (BMS) or KEYTRUDA (Merck), which target PD-1, have been used off-label or in clinical trials for metastatic uveal melanoma; however, their efficacy in this type of melanoma is limited compared to their effectiveness in cutaneous melanoma.

DelveInsight’s analysis indicates that the ocular melanoma clinical trials market is very active, with many investigational therapies at various development stages. Notable candidates include TBio-4101 (Turnstone Biologics), LNS8801 (Linnaeus Therapeutics), IOA-244 (iOnctura), SD-101 (TriSalus Life Sciences), and BVD-523 (Dana-Farber Cancer Institut/BioMed Valley Discoveries), among others. These emerging therapies represent significant advancements in the ocular melanoma treatment landscape, providing hope for improved survival rates and quality of life for patients with limited options.

Recently, in March 2025, IDEAYA Biosciences (NASDAQ: IDYA) received FDA Breakthrough Therapy Designation for darovasertib, a novel PKC inhibitor, as a neoadjuvant treatment for uveal melanoma. This designation was granted based on phase II trial data showing significant tumor shrinkage, eye preservation, and a manageable safety profile with low rates of severe adverse events.

In January 2025, the FDA awarded orphan drug status to an aptamer drug conjugate (ApDC) treatment developed by researchers in China. This gene-based therapy precisely delivers anti-tumor drugs to cancer cells, making it safer and more effective than traditional methods such as surgery and radiotherapy. These developments signal promising progress in the ocular melanoma clinical trials market.

Unlock which Ocular Melanoma emerging drug is expected to capture the largest market share in 7MM by 2034. Visit the Ocular Melanoma Drug Insights.

The comprehensive analysis of the ocular melanoma market indicates promising growth prospects through 2034, supported by advancements in diagnostics and therapeutics, increasing prevalence of the disease, and rising healthcare investments globally. Stakeholders across the pharmaceutical industry, healthcare providers, and investors can leverage these insights to navigate the evolving landscape effectively and contribute to improved patient outcomes in ocular melanoma management.

Table of Contents

1.	Key Insights
2.	Report Introduction
3.	Executive Summary of Ocular Melanoma
4.	Ocular Melanoma Market Overview at a Glance
5.	Key Events
6.	Ocular Melanoma Epidemiology and Market Forecast Methodology
7.	Ocular Melanoma: Disease Background and Overview
8.	Ocular Melanoma Treatment
9.	Ocular Melanoma Epidemiology and Patient Population
10.	Ocular Melanoma Patient Journey
11.	Ocular Melanoma Marketed Therapies
12.	Emerging Ocular Melanoma Drugs
13.	Key Cross
14.	Ocular Melanoma: Market Analysis
15.	Ocular Melanoma Unmet Needs
16.	SWOT Analysis
17.	KOL Views
18.	Market Access and Reimbursement
19.	Appendix
20.	DelveInsight Capabilities
21.	Disclaimer
22.	About DelveInsight

Related Reports

Melanoma Pipeline Insight

Melanoma Pipeline Insight provides comprehensive insights about the melanoma pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the melanoma companies, including IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics LLC, Nykode Therapeutics, Achilles Therapeutics UK Limited, Evaxion Biotech, InxMed, AiVita Biomedical, Cytovation AS, Ono Pharmaceuticals, Neon Therapeutics, and Iovance Biotherapeutics, among others.

About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Ocular Melanoma Market is Expected to Grow Substantially from USD 340 Million in 7MM by 2034 | DelveInsight

Brenmiller Energy: The Thermal Energy Workhorse the Market Needs to Meet (NASDAQ: BNRG)

The energy transition conversation has become an echo chamber—buzzwords, mega-million-dollar raises, and dazzling investor decks from companies long on promises but short on proof. Batteries, hydrogen, carbon capture—all pitched as silver bullets, yet most are still stuck in pilot mode. Amid the noise, one company isn’t pitching the future—it’s building it. Brenmiller Energy (NASDAQ: BNRG), the Israeli-based thermal energy storage (TES) pioneer with projects across the U.S., Europe, and the Middle East, has quietly become a player in clean industrial heat. Not one of many. As of now—the one.

That’s no exaggeration. While others continue to refine concepts and run simulations, Brenmiller is executing at scale. Its flagship bGen™ technology stores heat from low-cost or renewable sources—such as solar, waste heat, or off-peak electricity—and releases it on demand 24/7/365. It’s already being deployed commercially, not in test beds, but in high-volume industrial environments, including Tempo Beverages, a Heineken subsidiary, where it’s expected to slash emissions and stabilize energy costs.

In other words, Brenmiller Energy isn’t a startup chasing relevance—it’s a commercial entity with revenue on the books, global contracts in place, and a project pipeline exceeding $500 million. While that’s happening, most “competitors” are still trying to engineer a breakthrough. And as Brenmiller installs systems and gets paid, Wall Street remains asleep at the switch.

Video Link: https://www.youtube.com/embed/gxnCDNU1Bho

Empowering Industrial Heat is Brenmiller’s Sweet Spot

That’s fine. It keeps the investment opportunity in play at the retail level. And it may deliver a handsome return. Keep in mind that, despite the spotlight on batteries and renewables, over 50% of global energy consumption is related to heat. That number increases in industrial production, noting that heat touches approximately 60% of production. Still, clean industrial heat barely registers in public discourse.

That’s not an oversight—it’s a blind spot. Batteries and alternative energy sources, such as hydrogen, dominate headlines, but neither is yet ready to scale cost-effectively for industrial heat. The result? Factories worldwide remain locked into fossil-fuel systems because the alternatives are either too expensive, too complex, or still in the development stage.

The point is— they don’t need to be boxed in. Brenmiller’s bGen™ system is deliverable today, integrates seamlessly, and decarbonizes heat processes immediately by turning renewable or surplus energy into steady, on-demand thermal power all day, every day. The better news is that it doesn’t compete with solar or wind—it enhances them.

Bridging a Gap Left by Other Clean Energy Sources

bGen™ fills the service gaps of sources like wind or solar, which can be an unreliable chain of energy custody when conditions aren’t right. Not the case for bGen. In all conditions, it stores cleanly generated excess power and discharges it as usable heat, which, by the way, also solves a major bottleneck in grid flexibility. It’s not just heat storage—it’s grid strategy.

Better still, the model scales, offering dual revenue streams through Heat-as-a-Service and infrastructure deployment. Also, remember that in a sector littered with “potentials,” Brenmiller is already in motion, with major brands on board, partnership support in place, and manufacturing capacity ramping. In other words, the gap between idea and implementation no longer exists—it’s been bridged.

And while the company is carving a first-mover advantage through crushed rock, it welcomes competition. As its COO recently said, TES isn’t a niche—it’s a multi-billion, someday trillion-dollar market opportunity. Even a sliver of that future can mean exponential returns for early players and their stakeholders. For now, though, the key difference between Brenmiller and potential competitors is that Brenmiller isn’t positioning itself to be one of those on-boarding players—it’s already in the game.

The World Gets It—But the Market Hasn’t Yet

And it’s being noticed. While U.S. markets remain slow to connect the dots, global accolades are pouring in. Brenmiller has racked up a trophy case of prestigious awards—each a validation of execution, not potential. Highlights include the European Commission’s Seal of Excellence, a finalist at BloombergNEF Pioneers 2024, TIME’s Best Inventions of 2023, and, most recently, a 2025 Gold Edison Award for Energy Storage and Management. These are not handed out for white papers or pitch decks. They are awarded to companies with technology that has proven to be effective, scalable, and already making a positive impact on the planet.

Yet, despite the recognition, the contracts, the partners, an aggressive plan to monetize new, competitively innovative systems through 2030, and the millions in assets on the ground, Brenmiller trades with a market cap of about $11.4 million at press time Tuesday. That’s not a typo. In the same space where private TES companies are raising hundreds of millions on projections and pilot systems, Brenmiller is already commercial—with less than 10 million shares outstanding. As of now, it’s the only pure-play public TES company available to retail investors, and it’s priced like a startup without revenue.

Consolidating at under $2/share, the discrepancy between valuation and value is staggering. A recalibration toward private-sector comps would justify a share price north of $50. Just place Brenmiller’s technology alongside development-stage startups—that proposition, while it implies a massive gain from its current share price, is supported.

And it’s not just about the upside—it’s about inevitability. With a growing pipeline, a clear path to profitability, and tangibles that warrant value, Brenmiller Energy is more than positioned for growth—it’s delivering it. Therefore, don’t misunderstand or miscalculate the opportunity—as industrial clients and governments confront decarbonization deadlines, the demand for clean heat solutions will surge.

When that moment hits—and it will—investors won’t be asking if Brenmiller can deliver. The only question will be why they didn’t see it coming and, perhaps more importantly from an investor perspective, didn’t capitalize when they had the chance.

Additional Disclaimers and Disclosures:Hawk Point Media Group, LLC. (HPM) has not been compensated to produce and distribute this content. It should be expressly understood that HPM is not operated by a licensed broker, a dealer, or a registered investment adviser. It should also be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. HPM reports/releases are commercial advertisements and are for general information purposes ONLY. The information made available by HPM is not intended to be, nor does it constitute, investment advice or recommendations. The contributors do NOT buy and sell securities covered before or after any particular article, report and/or publication. HPM holds ZERO shares in Brenmiller Energy Ltd. Always do your own due diligence prior to investing in any publicly traded company. While HPM has not been compensated for creating and syndicating this content, HPM discloses having a prior services agreement with the company and third parties that expired in April 2025 and 2024, respectively. HPM is a digital marketing and consulting company. Therefore, it is possible that HPM will be retained in the future to create and syndicate digital content for Brenmiller Energy. Accordingly, while fact-based and sourced, our content may portray featured companies in only the most favorable way. A complete disclosure for all services provided and compensated for is linked below. Forward-Looking Statements: This article contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Statements that are not statements of historical fact may be deemed to be forward-looking statements. The forward-looking statements contained or implied in this article are subject to other risks and uncertainties, many of which are beyond the control of the Company featured or HPM. Hawk Point Media Group, Llc. undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. For Hawk Point Media Group Llc’s full disclaimer and disclosure statement, click HERE.

Media Contact
Company Name: Hawk Point Media
Contact Person: Editorial Dept.
Email: info@hawkpointmedia.com
Country: United States
Website: https://hawkpointmedia.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Brenmiller Energy: The Thermal Energy Workhorse the Market Needs to Meet (NASDAQ: BNRG)

Chronic Spontaneous Urticaria Market Set for Robust Growth From USD 2 Billion in 2023 with a CAGR of 10% | DelveInsight

“Chronic Spontaneous Urticaria Market Delveinsight”

Key chronic spontaneous urticaria companies driving innovation include United BioPharma, Teva Pharmaceuticals Development Inc., Amgen, Novartis Pharmaceuticals, Allakos Inc., Sanofi, Celltrion, Celldex Therapeutics, MICROBIO GROUP, Escient Pharmaceuticals, Jasper Therapeutics, Glenmark Pharmaceuticals, Taiho Pharmaceuticals, ValenzaBio, Carna Biosciences, and Servier, among others.

DelveInsight’s “Chronic Spontaneous Urticaria Market Insight, Epidemiology And Market Forecast—2034” report provides an in-depth understanding of chronic spontaneous urticaria, its historical and forecasted epidemiology, and the chronic spontaneous urticaria market trends in the 7MM, which include the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

According to the report, the chronic spontaneous urticaria treatment landscape is poised for significant transformation as the market size, valued at approximately USD 2 billion in 2023, is projected to expand at a CAGR of over 10% through 2034. This growth trajectory is being fueled by the introduction of innovative therapies targeting new pathways, improved diagnostic capabilities, and rising disease awareness. The chronic spontaneous urticaria market continues to attract substantial investment from leading pharmaceutical companies seeking to address significant unmet needs in a condition that severely impacts patients’ quality of life.

The US dominates the chronic spontaneous urticaria market landscape, accounting for USD 1.2 billion in 2023, representing over half of the 7MM market. This robust growth is largely driven by favorable reimbursement policies and the rapid adoption of premium-priced therapies. Meanwhile, the EU4 and UK collectively contribute approximately USD 600 million, with Germany leading at USD 160 million, followed by France. Japan accounts for 18% of the 7MM market, valued at approximately USD 380 million.

Download the Chronic Spontaneous Urticaria Market report to understand which factors are driving the Chronic Spontaneous Urticaria therapeutic market @ Chronic Spontaneous Urticaria Market Trends.

The chronic spontaneous urticaria patient pool is substantial, with DelveInsight’s epidemiology model estimating approximately 4.1 million diagnosed prevalent cases across the 7MM in 2023. Among these markets, Japan bears the highest burden with nearly 1 million cases, followed by the US with approximately 500K cases. Furthermore, gender distribution analysis reveals a significant female predominance, with EU4 and the UK reporting 840K female cases compared to 390K male cases in 2023, highlighting important demographic considerations for targeted therapeutic development.

Discover evolving trends in the Chronic Spontaneous Urticaria patient pool forecasts @ Chronic Spontaneous Urticaria Epidemiology Analysis.

The chronic spontaneous urticaria treatment market report also provides insights into current chronic spontaneous urticaria treatment practices, emerging drugs, the market share of individual therapies, and forecasts for emerging drugs in the 7MM from 2020 to 2034.

The current chronic spontaneous urticaria treatment paradigm follows a stepwise approach, beginning with second-generation H1-antihistamines as first-line therapy, followed by up-dosing to fourfold in refractory cases. For patients unresponsive to antihistamines, Roche/Novartis’s XOLAIR, a recombinant DNA-derived humanized IgG1k monoclonal antibody that selectively binds to IgE, remains the cornerstone therapy, generating approximately USD 913 million in US revenue in 2023. The recent approval of Sanofi/Regeneron’s DUPIXENT by Japan’s MHLW in February 2024 for chronic spontaneous urticaria patients aged 12 years and older introduces a valuable alternative mechanism targeting IL-4 and IL-13 signaling pathways.

The chronic spontaneous urticaria competitive landscape is evolving rapidly, with several promising candidates advancing through clinical development. Novartis Pharmaceuticals’ remibrutinib, an oral Bruton’s tyrosine kinase inhibitor, has demonstrated significant long-term efficacy and safety in Phase III trials (REMIX-1 and REMIX-2), with regulatory submission planned for 2025. AstraZeneca and Amgen’s TEZSPIRE, a first-in-class monoclonal antibody inhibiting thymic stromal lymphopoietin, has completed Phase II trials, while Sanofi’s rilzabrutinib (SAR444671), another oral BTK inhibitor, showed positive results in the Phase II RILECSU study with a Phase III program on the horizon.

Recent regulatory milestones underscore the dynamic nature of the chronic spontaneous urticaria market. In March 2025, Celltrion secured FDA approval for OMLYCLO (omalizumab-igec) as the first interchangeable biosimilar to XOLAIR, potentially improving treatment access and affordability. Additionally, the FDA’s acceptance of the resubmitted supplemental biologics license application for DUPIXENT in November 2024 could further diversify treatment options for patients with inadequate response to H1-antihistamines.

Unlock which Chronic Spontaneous Urticaria emerging drug is expected to capture the largest market share in 7MM by 2034. Visit the Chronic Spontaneous Urticaria Drug Insights.

Despite therapeutic advances, significant challenges persist in chronic spontaneous urticaria management. Nearly one-third of patients remain symptomatic despite omalizumab treatment, and the subcutaneous administration route creates an additional burden for healthcare systems and patients. The high cost of biologics limits accessibility, particularly in restricted healthcare environments where more affordable options like H2-antagonists and dapsone maintain relevance despite not being included in formal treatment guidelines. These unmet needs highlight the importance of continued innovation in developing cost-effective, convenient, and efficacious treatments for this challenging dermatological condition.

Table of Contents

1.	Key Insights
2.	Report Introduction
3.	Chronic Spontaneous Urticaria Market Overview at a Glance
4.	Methodology of Chronic Spontaneous Urticaria Epidemiology and Market
5.	Executive Summary of Chronic Spontaneous Urticaria
6.	Key Events
7.	Chronic Spontaneous Urticaria Disease Background and Overview
8.	Chronic Spontaneous Urticaria Patient Journey
9.	Chronic Spontaneous Urticaria Epidemiology and Patient Population
10.	Chronic Spontaneous Urticaria Marketed Drugs
11.	Chronic Spontaneous Urticaria Emerging Drugs
12.	Chronic Spontaneous Urticaria: Market Analysis
13.	Key Opinion Leaders’ Views
14.	SWOT
15.	Chronic Spontaneous Urticaria Unmet Needs
16.	Market Access and Reimbursement
17.	Appendix
18.	DelveInsight Capabilities
19.	Disclaimer

Chronic Spontaneous Urticaria Pipeline Insight provides comprehensive insights about the chronic spontaneous urticaria pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the chronic spontaneous urticaria companies, including United BioPharma, Teva Pharmaceuticals Development Inc., Amgen, Novartis Pharmaceuticals, Allakos Inc., Sanofi, Celltrion, Celldex Therapeutics, MICROBIO GROUP, Escient Pharmaceuticals, Jasper Therapeutics, Glenmark Pharmaceuticals, Taiho Pharmaceuticals, ValenzaBio, Carna Biosciences, and Servier, among others.

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Spontaneous Urticaria Market Set for Robust Growth From USD 2 Billion in 2023 with a CAGR of 10% | DelveInsight

NUBURU (BURU) Secures $3.4M Debt Resolution, Targets Revenue with Defense Sector Expansion

“We are excited to share these strategic updates with our shareholders and underscore our focus on creating significant value through our dual business lines,” said Alessandro Zamboni, Executive Chairman of NUBURU.

NUBURU, Inc. (NYSE American: BURU) announced a significant financial breakthrough that investors should take note of. The high-power blue laser technology pioneer has secured funding partners to address approximately $3.4 million in accounts payable accumulated under previous management. This development represents more than just debt reduction—it signals a critical turning point in the company’s financial trajectory.

For investors following NUBURU’s transformation story, this announcement builds upon the company’s recent $5.15 million convertible funding commitment with Supply@ME Capital Plc (SYME). The strategic partnership with SYME is particularly noteworthy as it introduces innovative fintech solutions that enable NUBURU to adopt a capital-light business model—a move that typically enhances return on invested capital and reduces operational risk.

Defense & Security: The New Growth Engine

What’s particularly compelling about NUBURU’s strategic update is the company’s targeted expansion into the defense and security sectors. The planned acquisition of a Defense & Security Hub positions NUBURU to leverage its proprietary blue laser technology for specialized defense applications while simultaneously developing SaaS security solutions.

From an investment perspective, this diversification strategy addresses a critical concern many tech-focused companies face: overreliance on a single technology or market segment. By extending its reach into defense applications and software services focused on operational resilience, NUBURU is building multiple revenue streams in high-margin, high-demand sectors.

Revenue Projection Analysis

Management projects that these strategic acquisitions could contribute over $50 million in revenue during 2025, pending regulatory and shareholder approvals. While this projection should be viewed with appropriate caution, it represents a substantial growth opportunity for a company that has been primarily focused on technology development and commercialization in manufacturing applications.

The projected $50 million revenue infusion would significantly alter NUBURU’s financial profile, potentially accelerating its path to profitability and positive cash flow generation.

Outstanding Concerns: Preferred Stock Redemption

Executive Chairman Alessandro Zamboni noted that the company is still working to address “the redemption obligations of the Company with respect to the outstanding Series A Preferred Stock.” This remains an important consideration for investors, as preferred stock redemption obligations can impact capital allocation decisions and potentially dilute common shareholders depending on the resolution mechanism.

Investment Outlook

NUBURU’s aggressive moves to clear legacy debt while simultaneously pursuing strategic acquisitions in high-growth markets create an intriguing investment case. For investors with appropriate risk tolerance, several factors merit attention:

Debt Resolution Progress: The clearing of $3.4 million in accounts payable strengthens the balance sheet and reduces financial risk.
Capital-Light Model: The SYME partnership enables NUBURU to maintain inventory flexibility without heavy capital investment.
Market Diversification: The expansion beyond manufacturing applications into defense and security broadens the company’s addressable market.
Revenue Growth Potential: The projected $50 million in acquisition-driven revenue would dramatically alter the company’s financial trajectory.
Management Execution: The new leadership team under Zamboni appears to be taking decisive action to reposition the company for growth.

Given its ongoing transformation, the company’s strategic pivot and debt resolution progress warrant closer attention from growth-oriented investors interested in advanced technology with defense and security applications. Other notable defense related stocks to keep on top of radar include TransDigm Group Inc. (NYSE: TDG), General Dynamics Corp. (NYSE: GD), Northrop Grumman Corp. (NYSE: NOC), Howmet Aerospace Inc. (NYSE: HWM), Axon Enterprise Inc. (NASDAQ: AXON), Curtiss-Wright Corp. (NYSE: CW), Embraer SA (NYSE: ERJ).

For more information, visit www.nuburu.net.

Disclaimer: This blog post is for informational purposes only and does not constitute financial advice or an endorsement of COEP or its strategies. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at https://UsaStockReport.com//disclaimer/. https://UsaStockReport.com/ has been compensated five hundred dollars by a 3rd party Carriage Consulting Group for content distribution services on BURU for April 23, 2025. https://UsaStockReport.com/ is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of https://UsaStockReport.com/ is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future results.https://UsaStockReport.com/ does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at https://www.sec.gov/edgar/searchedgar/companysearch. It is always important to conduct thorough due diligence and exercise caution in trading.https://UsaStockReport.com/ is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by https://UsaStockReport.com/ or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. https://UsaStockReport.com/ is not a fiduciary by virtue of any person’s use of or access to this content. This article is for informational purposes only and does not constitute investment advice. Always conduct your own research before making investment decisions.

Source: https://finance.yahoo.com/news/nuburu-secures-funding-eliminate-outstanding-125100783.html

Media Contact
Company Name: UsaStockReport
Contact Person: Ash K
Email: editor@usastockreport.com
City: Frisco
State: Texas
Country: United States
Website: https://usastockreport.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: NUBURU (BURU) Secures $3.4M Debt Resolution, Targets Revenue with Defense Sector Expansion

Signpost Expands Live Receptionist Services to Better Serve Skilled Trades Across the U.S.

Signpost, a leader in business communication solutions, has announced the expansion of its live receptionist services to better support tradespeople and contractors in key industries across the United States. As demand for immediate customer response continues to grow, Signpost is stepping up to provide 24/7 live answering services tailored to meet the specific needs of electricians, plumbers, roofers, HVAC professionals, and general contractors.

The company’s live receptionist service is designed to address one of the most common challenges in the skilled trades—missed calls that lead to missed business opportunities. With consumers expecting prompt and professional responses, businesses that fail to answer the phone risk losing out. Signpost’s solution helps bridge that gap, providing a reliable and professional first point of contact for potential clients, while allowing contractors to stay focused on the job at hand.

Live Answering Support Designed for the Trades

One of the most in-demand offerings is the Live Receptionist For Electricians, a solution crafted to help electrical contractors manage incoming inquiries while staying on-site and on-task. Missed calls during installations or service calls can be costly, and Signpost’s trained receptionists ensure that every lead is captured and handled with care.

Similarly, Signpost is now offering its tailored Live Receptionist For General Contractors, understanding the hectic schedules and job site demands these professionals face daily. Whether managing crews, meeting with clients, or coordinating with suppliers, contractors benefit from knowing their calls are being answered in real time by a professional who can schedule appointments, provide basic information, or take detailed messages.

Responsive Communication in a Competitive Market

For plumbing professionals, fast response times are essential. Signpost has rolled out its Live Receptionist For Plumbers to ensure that calls don’t go unanswered during emergencies or peak service hours. Each receptionist is trained to handle plumbing-specific inquiries, offering a smooth and informed experience for the caller while maximizing lead conversion for the business.

The same level of responsiveness is extended to the Live Receptionist For HVAC Contractors, a service especially critical during seasonal spikes in demand. From scheduling maintenance calls to managing service emergencies, Signpost’s receptionists work as a seamless extension of the HVAC business, giving callers the confidence that their issue are being addressed promptly.

Finally, recognizing the importance of capturing leads for roofing services, especially after storms or in peak season, Signpost has launched its Live Receptionist For Roofers. Roofing companies benefit from having a live point of contact available around the clock, ensuring no call is missed regardless of time or volume.

Building Stronger Connections Between Trades and Clients

Signpost’s live receptionist services are not just about answering phones—they also build trust and convert leads into loyal customers. Every call is an opportunity, and with trained professionals managing incoming communication, trade businesses can make the most of every one.

About Signpost

Signpost is a leading communication and marketing platform helping small and medium-sized businesses grow through better customer engagement. With tools designed to simplify communication, automate follow-ups, and capture more leads, Signpost supports a wide range of industries, from home services to healthcare. The company aims to help businesses build stronger customer relationships through reliable, efficient, and scalable solutions.

Media Contact
Company Name: Signpost
Contact Person: Lucas Wilson
Email: Send Email
Phone: (844) 202-2015
Address:234 5th Ave fl 2
City: New York
State: NY
Country: United States
Website: https://www.signpost.com/

Driving Inclusion: REHACARE CHINA 2025 will be held in Suzhou this August

16 April, 2025 – Shanghai – The International Trade Fair for Rehabilitation and Care will be held from August 21-23 at the Suzhou International Expo Center in 2025. Themed “Driving Inclusion”, the 3-day Exhibition and Conference will showcase a wide range of products, including rehabilitation robots, exoskeletons, elderly care rehabilitation supplies, sports rehabilitation products, smart rehabilitation solutions, home medical devices, hearing aids, cardiopulmonary rehabilitation products, and elderly-friendly facilities. The goal is to create a one-stop platform for sourcing, networking, and exchange across the entire rehabilitation industry chain, and to become a “trendsetter” for the rehabilitation industry.

According to the National Bureau of Statistics, China’s population aged 60 and above surpassed 310 million by 2024, accounting for 22% of the total population. The silver economy is growing at a compound annual growth rate (CAGR) of 17.3% and is expected to surpass RMB 12.8 trillion by 2025. The fastest-growing categories, smart health devices and elderly-friendly home solutions are witnessing an annual growth rate of over 200%. Furthermore, the recently concluded Third Session of the 14th National People’s Congress approved the Government Work Report which highlighted the importance of expanding the supply of diversified services, including health care, elderly care, disability support, and domestic services by relaxing access, reducing restrictions and optimizing regulations with a strong focus on accelerating the development of smart elderly care.

The pressing need to intensify the development of smart health care and elderly care, and to address the “last mile” challenge in integrating medical and elderly care has become increasingly urgent.

Empowering Rehabilitation with Technology, Helping Enterprises to Efficiently Expand Domestic and Global Market Presence

REHACARE CHINA 2025 will cover an area of 15,000 square meters (held concurrently with MFC 2025) and feature four key exhibition zones: the Intelligent Rehabilitation Zone, the Sport Rehabilitation Zone, the Hearing Aids Zone, and the International Innovation Zone. Over 200 domestic and international companies specializing in rehabilitation medical devices will showcase cutting-edge products, innovative technologies, and applications, while engaging in stimulating industry discussions. The organizer will capitalize on the strengths of this international platform, striving to bring in leading overseas enterprises, while helping outstanding Chinese enterprises expand globally.

Kangni Smart、Vigorous、Boin Hearing、Dahao Medical、Innuovo、JMC、Neural Galaxy Healthcare、Sunrise Medical、Hubang、RoboCT、BrainCo、BEWATEC、KANGHUI、Mateside、ZUOWEI、Sweetrich、Kaiyang、Soundlink、Shininglion、Weiyu、Real Star Rehab、Super PI Robot、Heins Medical、Illinois、iSUN3D、Kind-Sound、Soft Robot Tech and other well-known companies will participate in the exhibition.

“This marked Boin Hearing’s debut at REHACARE CHINA 2024, an event we highly prioritized by showcasing our latest products developed in-house,” said Mr. Shi Weigang, the General Manager of Boin Hearing Device (Suzhou) Co., Ltd. “The turnout and caliber of the visitors were exceptional, with our booth bustling throughout the event. This clearly indicates an escalating demand for rehabilitation products.”

Innovating for Inclusion: “Industry-Academia-Research-Application” Talks Series to Drive Cutting-edge Transformations

This year, various forums will be organized such as:

– The “Belt and Road” Yangtze River Delta Rehabilitation Medicine Forum

– The “Neuroscience and Technology” Rehabilitation Forum

– The “Silver Economy” Health and Elderly Care Forum

– The Autism Care and Rehabilitation Forum

– The Sports Rehabilitation Development Forum

– The Hearing Impairment Prevention and Rehabilitation Sharing Conference

– The Rehabilitation Distributor Forum

Furtherly, to provide a better exhibition experience for both exhibitors and trade visitors, Yangtze River Delta Rehabilitation Equipment Procurement Matchmaking Event will be unveiled this year. Dearlers and retailers will be wildly invited in national wide. In addition, a special “Adaptive Sports Experience Zone” will be set up on-site, designed to inspire people with disabilities to rekindle their determination to return to normal life. This zone will also provide new perspectives and ideas for professionals in rehabilitation and care.

Multi-Channel Marketing to Boost Product Visibility and Enhance Brand Presence

REHACARE CHINA has partnered with leading domestic and international media outlets, industry-specific platforms, Key Opinion Leaders (KOLs) to create a comprehensive multimedia strategy, maximize brand visibility for exhibitors and improve conversion rates. REHACARE CHINA will feature extensive domestic coverage from prominent media organizations such as People’s Daily Online, Xinhua Net, CCTV News, VC Beat, Rehab Community, and Kangzhiliao. In addition, rehabilitation KOLs will be invited to explore the exhibition, providing exhibitors with various product exposure opportunities across multiple scenarios. On the international front, the organizer will collaborate with global media partners, including Medhealth Outlook, HealthCare Asia, and MedicaEx, and also leverage social media platforms such as LinkedIn, Facebook, and X (formerly Twitter) to promote the event. This will help the event reach over 10 countries and regions, including the United States, Malaysia, Singapore, Taiwan China, Thailand, Indonesia, South Korea, and more.

About REHACARE CHINA:

Launched in 2023 by the Messe Düsseldorf Group and organized by its subsidiary Messe Düsseldorf (Shanghai) Co., Ltd., REHACARE CHINA is dedicated to creating a professional platform for China’s aging population, people with disabilities, and others in need of rehabilitation services, promoting deeper social integration. The exhibition showcases a wide range of products and services, including assistive devices, elderly care services, rehabilitation medical equipment and technologies, rehabilitation management, daily care, and elderly- friendly renovations and construction. The goal is to establish an accurate international procurement and supply matchmaking platform, fostering collaboration and communication across the entire rehabilitation industry chain.

About Messe Düsseldorf (Shanghai) Co., Ltd

Established in 2009, Messe Düsseldorf (Shanghai) Co., Ltd. (MDS) is a subsidiary of Messe Düsseldorf GmbH, one of the world’s top exhibition organizers. Messe Düsseldorf Shanghai (MDS) is committed to introducing industry leading trade fairs to China and providing Chinese and international customers with superior exhibition services. MDS is successfully holding 13 leading trade fairs and conferences in China, covering a broad range of industries including printing packaging, wire and tube, plastics, medical devices, rehabilitation, retail, safety and health, wine & spirits and caravanning. With a workforce of more than 70 full-time employees, the company’s head office is located in Shanghai with a branch office in Beijing.

For more information about MDS, please visit www.mds.cn.

About MEDICARE ASIA

REHACARE CHINA is an initiative by MEDICARE ASIA – the central business platform for all attendees to Messe Düsseldorf’s current portfolio of nine medical and healthcare exhibitions throughout Asia. It seeks to foster strategic alliances, innovate new offerings and develop customer-centric strategies to engine our portfolio for growth in the vast and diverse continent – Asia. It also seeks to build a strong channel from Asia to our global-leading trade shows in Düsseldorf – MEDICA, COMPAMED, and REHACARE. Through MEDICARE ASIA, attendees will benefit from harmonized offerings that are tailored to their needs, central point of contact and stronger business platforms – both in Asia and Düsseldorf.

Media Contact
Company Name: Messe Düsseldorf (Shanghai) Co., Ltd | Beijing Branch Office
Contact Person: Ms. Lv
Email: Send Email
Phone: +86-10 6590 7101 ext. 8626
Country: China
Website: www.mds.cn

Humane Foundation Launches Renewed Global Movement to End Factory Farming and Inspire a Future of Compassionate Living

What if animal cruelty became history? The Humane Foundation invites the world to imagine—and create—a future where factory farming is no longer a grim reality, but a distant memory we’ve overcome with pride. With their flagship platform Cruelty.Farm, the foundation is doubling down on efforts to educate, expose, and empower individuals, policymakers, and organizations to build a compassionate, sustainable, and healthier world.

A Unified Vision for Change

“In unity, let’s dream of a world where animals no longer suffer silently,” says Ali Roghani, Executive Director of the Humane Foundation. “We envision a day when we can speak about the age of factory farming in the past tense, where animals no longer weep, but thrive—and where the health of people and the planet are protected with unwavering priority.”

This vision powers every project under the Humane Foundation. From in-depth investigations to multilingual education, and from plant-based food innovation to legal advocacy, the foundation is one of the world’s most comprehensive and forward-thinking organizations working to end factory farming.

Revealing the Truths Behind the System

Animal agriculture today is a hidden crisis. On the surface, it fuels global food supply chains. But behind the barn doors lies a harrowing truth: billions of animals are confined to overcrowded, filthy cages; mutilated without anesthesia; and denied every natural behavior. The foundation’s platform, Cruelty.Farm, exposes this reality with video investigations, reports, and survivor stories—available in over 80 languages.

The site acts as a gateway to truth, knowledge, and action. Visitors can access content that unveils how factory farming:

Inflicts unbearable suffering on animals through tight confinement, mutilation, and systemic abuse
Threatens human health through the overuse of antibiotics, contributing to antibiotic resistance
Pollutes water and air, including through chemical runoff and greenhouse gas emissions
Accelerates deforestation and climate change through unsustainable land use practices

Inspiring Alternatives: Plant-Based, Ethical, and Local

The Humane Foundation believes in solutions—not just problems. One of the core paths forward is the promotion of plant-based living and ethical, local food systems. The foundation supports the creation and adoption of plant-based alternatives that don’t just eliminate suffering—they nourish bodies, reduce environmental strain, and uplift communities.

A powerful message runs through every campaign: compassion is a choice. Whether it’s by choosing a plant-based meal, supporting local farmers who practice ethical agriculture, or advocating for policy changes, every action counts.

Explore guidance for shifting to a plant-based lifestyle at Promoting Animal Welfare Through Plant-Based Diets.

Building a Compassionate Ecosystem

The foundation operates with a multi-layered approach—combining grassroots outreach, government engagement, corporate partnerships, and global coalitions. Through education, policy influence, and strategic partnerships, the Humane Foundation fights to shift systems—not just minds.

Key pillars of the foundation’s mission include:

Education: Equipping the public with the knowledge to make ethical and informed decisions
Advocacy: Driving policy change to protect animals, public health, and the environment
Community Engagement: Encouraging individuals to become agents of change in their own neighborhoods
Innovation: Supporting research and development in sustainable food and animal welfare

Take action today by visiting cruelty.farm/take-action

Everyone Has a Role

“We are united by a common dream—0% cruelty, 100% compassion,” says Mr. Roghani. “Whether you’re a student, an activist, a policymaker, or just someone who loves animals, there’s a place for you in this movement.”

You can get involved by:

Sharing plant-based meals with your community
Supporting local and ethical farmers
Advocating for better animal welfare laws
Donating to support life-changing investigations and education
Educating others about the true cost of factory-farmed food

Even small acts spark big change—and those sparks can build the flame of a better world.

The Next Era: Compassion, Fairness, and Sustainability

With global interest in sustainable and ethical living on the rise, the Humane Foundation is poised to help usher in a new era—an era of fairness, compassion, and conscious coexistence. Backed by science, driven by empathy, and powered by community, the organization sees hope on the horizon.

“Now is the moment,” the foundation declares. “The statistics show it. The science confirms it. And the people are ready. The coming decades will be defined by how deeply we are willing to care—about animals, each other, and the earth we all share.”

About Humane Foundation

The Humane Foundation is a self-funded non-profit organization registered in the UK (Reg No. 15077857), dedicated to eliminating factory farming and creating a food system rooted in compassion, sustainability, and justice. With a multilingual digital platform, innovative campaigns, and strategic collaborations, the foundation inspires people worldwide to align their actions with their deepest values.

Registered Address: 27 Old Gloucester Street, London, United Kingdom, WC1N 3AX

Media Contact
Company Name: Humane Foundation
Contact Person: Ali Roghani
Email: Send Email
Address:27 Old Gloucester Street
City: London
State: England
Country: United Kingdom
Website: https://cruelty.farm/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Humane Foundation Launches Renewed Global Movement to End Factory Farming and Inspire a Future of Compassionate Living

Future Electronics to Host Employee Resilience Seminar at Pointe Claire Headquarters

Future Electronics will present “Resiliency at Work,” a professional development seminar for employees at its Pointe Claire Headquarters, featuring expert strategies for building workplace resilience and managing stress effectively.

Montreal, Canada – April 22, 2025 – Future Electronics, a global leader in electronic components distribution, will conduct an exclusive “Resiliency at Work” seminar for employees at its Pointe Claire headquarters on June 2 and June 4 from 1:00 to 2:00 PM ET. The professional development session, presented by TELUS, will provide practical techniques for developing personal and professional resilience in demanding work environments.

The seminar will explore the fundamental components of resilience, examining how attitudes, decisions and coping mechanisms influence stress management. Participants will learn to differentiate between various stress types and their health impacts while acquiring actionable strategies for recovering from workplace challenges. The program emphasizes developing skills to not just endure but thrive under pressure.

The event forms part of Future Electronics’ comprehensive Learning professional education program, which regularly offers skill-building opportunities for employees. The company encourages staff to propose additional workshop ideas.

Future Electronics continues to demonstrate industry leadership through innovative employee development initiatives alongside its award-winning customer service. For more information on career opportunities at Future Electronics, visit: www.futureelectronics.com/careers

About Future Electronics:

Founded in 1968, Future Electronics is a global leader in the electronic components industry. Future Electronics’ award-winning customer service, global supply chain programs and industry-leading engineering design services have made the company a strategic partner of choice.

Headquartered in Montreal, Canada, Future Electronics operates in 159 offices across 44 countries with over 5,000 employees. Its worldwide presence powers the company’s outstanding service and efficient, comprehensive global supply chain solutions. Future Electronics is globally integrated and supported by one IT infrastructure which provides real-time inventory availability and enables fully integrated operations, sales and marketing services worldwide. In 2024, Future became a WT Microelectronics company, now dual-headquartered in both Montreal, Canada and Taipei City, Taiwan.

Future Electronics’ mission is always to Delight the Customer®. For more information visit www.FutureElectronics.com.

Media Contact
Company Name: Future Electronics
Contact Person: Jamie Singerman
Email: Send Email
Phone: 514-694-7710
Address:237 Hymus Boulevard
City: Pointe Claire
State: Quebec
Country: Canada
Website: https://www.futureelectronics.com/